JAM-A Antibody (160407) [Alexa Fluor® 647]

• Reactivity: Mu
• Applications: WB
• Clone: 160407
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Alexa Fluor 647

JAM-A Antibody (160407) [Alexa Fluor® 647] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant mouse JAM-A
  Lys27-Ala242
  Accession # O88792
• Specificity: Detects mouse JAM-A in direct ELISAs and Western blots. In direct ELISAs and Western blots, this antibody does not cross‑react with recombinant human JAM‑A.
• Source: N/A
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Rat
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for JAM-A Antibody (160407) [Alexa Fluor® 647]

• CD321 antigen
• CD321
• F11 receptor
• F11R
• JAM-1
• JAM1CD321
• JAMA
• JAM-A
• JCAMJAM
• Junctional adhesion molecule 1Platelet F11 receptor
• junctional adhesion molecule A
• PAM-1
• PAM-1KAT
• Platelet adhesion molecule 1

Background

The family of junctional adhesion molecules (JAM), comprising at least three members, are type I transmembrane receptors belonging to the immunoglobulin (Ig) superfamily (1, 2). These proteins are localized in the tight junctions between endothelial or epithelial cells. Some family members are also found on blood leukocytes and platelets. Mouse JAM-A is predominantly expressed at intercellular junctions of both epithelial cells and endothelial cells (3). It is also expressed on circulating megakaryocytes. Mouse JAM-A cDNA predicts a 300 amino acid (aa) residue precursor protein with a putative 23 aa signal peptide, a 215 aa extracellular region containing two Ig-like V-subset domains, a 17 aa transmembrane domain and a 45 aa cytoplasmic domain. The human and mouse protein share approximately 67% aa sequence homology. Mouse JAM-A also shares approximately 35% aa sequence homology with mouse JAM-B or JAM-C. JAM-A exhibits homotypic interactions to regulate tight junction assembly and modulate paracellular permeability (1 - 3). The human JAM-A homotypic interation also mediates platelet aggregation and adhesion to endothelial cells and may play a role in thrombosis (4). JAM-A is involved in leukocyte adhesion and transmigration through the endothelium (3, 5). JAM-A has also been shown to bind reovirus attachment protein sigma-1 to permit reovirus infection and signal virus-induced apoptosis (6).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • O88792()